UK national guideline for the management of gonorrhoea in adults, 2011

International Journal of STD and AIDS

Volumn 22, Issue 10, 2011, Pages 541-547

  Bignell, C ^a   Fitzgerald, M ^b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

Author keywords

Anti bacterial agents; Antibiotics; Disease management; Gonorrhoea; Guideline; Treatment; UK

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFOXITIN; CEFPODOXIME; CEFTRIAXONE; CIPROFLOXACIN; OFLOXACIN; PENICILLIN G; PROBENECID; QUINOLONE DERIVATIVE; SPECTINOMYCIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BREAST FEEDING; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONJUNCTIVA; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FINANCIAL MANAGEMENT; GASTROINTESTINAL SYMPTOM; GONORRHEA; HEALTH CARE ORGANIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION; PATIENT INFORMATION; PHARYNX; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; RECTUM; SINGLE DRUG DOSE; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CEFTRIAXONE; DISEASE MANAGEMENT; FEMALE; GONORRHEA; HUMANS; MALE; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; SEXUALLY TRANSMITTED DISEASES;

EID: 80054750360     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2011.011267     Document Type: Article

References (70)

1. Kingston M, Radcliffe K, Daniels D, et al. British Association for Sexual Health and HIV: framework for guideline development and assessment. Int J STD AIDS 2010;21:453-56
2. Sherrard J, Barlow D. Gonorrhoea in men: clinical and diagnostic aspects. Genitourin Med 1996;72:422-26
3. Barlow D, Phillips I. Gonorrhoea in women: diagnostic, clinical and laboratory aspects. Lancet 1978;i:761-64
4. Lewis DA, Bond M, Butt KD, et al. A one-year survey of gonococcal infection seen in the genitourinary medicine department of a London district general hospital. Int J STD AIDS 1999;10:588-94
5. Health Protection Agency. All new STI episodes seen at GUM clinics in the UK: 1999-2008. See http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1215589014474 (last accessed 10 February 2010).
6. Department of Health, Health Protection Agency and BASHH. Guidance for gonorrhoea testing in England and Wales. See http://www.bashh.org/news/478_2010-hpa-guidance-on-gonorrhoea-testing (last accessed 1 September 2011)
7. Sexually Transmitted Infections. UK National Screening and Testing Guidelines. See http://www.bashh.org/documents/59/59.pdf (under revision September 2010)
8. Whiley DM, Garland SM, Harnett G, et al. Exploring 'best practice' for nucleic acid detection of Neisseria gonorrhoeae. Sex Health 2008;5:17-23
9. Van Dyck E, Ieven M, Pattyn S, et al. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by enzyme immunoassay, culture and three nucleic acid amplification tests. J Clin Microbiol 2001;39:1751-56
10. Cook RL, Hutchison SL, Østergaard L, et al. Systematic review: non-invasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005;142:914-25
11. Martin DH, Cammarata C, Van der Pol B, et al. Multicenter evaluation of AMPLICOR and Automated COBAS AMPLICOR CT/NG tests for Neisseria gonorrhoeae. J Clin Microbiol 2000;38:3544-49
12. Moncada J, Schachter J, Hook EW, et al. The effect of urine testing in evaluations of the sensitivity of the Gen-Probe APTIMA Combo 2 assay on endocervical swabs for Chlamydia trachomatis and Neisseria gonorrhoeae. Sex Transm Dis 2004;31:273-77
13. Van der Pol B, Ferrero DV, Buck-Barrington L, et al. Multicenter evaluation of the BDProbeTec ET system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical and male urethral swabs. J Clin Microbiol 2001;39:1008-16
14. Chernesky MA, Martin DH, Hook EW, et al. Ability of new APTIMA CT and APTIMA GC assays to detect Chlamydia trachomatis and Neisseria gonorrhoeae in male urine and urethral swabs. J Clin Microbiol 2005;43:127-31
15. Schachter J, Chernesky MA, Willis DE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis 2005;32:725-28
16. Association of Public Health Laboratories. Laboratory diagnostic testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Expert Consultation Meeting Summary Report. 13-15 January 2009. Atlanta, GA, Silver Spring, MD: Association of Public Health Laboratories, 2009. See http://www.aphl.org/aphlprograms/infectious/std/documents/ctgclabguidelinesmeetingreport.pdf (last accessed 1 September 2011)
17. Schachter J, Moncada J, Liska S, et al. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections in the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008;35:637-42
18. Ota KV, Tamari IE, Smieja M, et al. Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in pharyngeal and rectal specimens using the BD Probetec ET system, the Gen-Probe Aptima Combo 2 assay and culture. Sex Transm Infect 2009;85:182-86
19. Benn PD, Rooney G, Carder C, et al. Chlamydia trachomatis and Neisseria gonorrhoeae infection and the sexual behaviour of men who have sex with men. Sex Transm Infect 2007;83:106-12
20. Page-Shafer K, Graves A, Kent C, et al. Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhoea in men who have sex with men. Clin Infect Dis 2002;34:173-76
21. Alexander S. The challenges of detecting gonorrhoea and chlamydia in rectal 46 Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health and pharyngeal sites: could we, should we, be doing more? Sex Transm Infect 2009;85:159-60
22. Palmer H, Mallinson H, Wood RL, Herring AJ. Evaluation of the specificities of five DNA amplification methods for the detection of Neisseria gonorrhoeae.J Clin Microbiol 2003;41:835-37
23. Health Protection Agency (2010). Detection of Neisseria gonorrhoeae using molecular methods. National Standard Method QSOP 62 Issue1. See http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop62.pdf (last accessed 1 September 2011)
24. Jephcott AE. Microbiological diagnosis of gonorrhoea. Genitourin Med 1997;73:245-52
25. Katz AR, Effler PV, Ohye RG, et al. False-positive gonorrhoea test results with a nucleic amplification test: the impact of low prevalence on positive predictive value. Clin Infect Dis 2004;38:814-19
26. McNally LP, Templeton DJ, Jin F, et al. Low positive predictive value of a nucleic acid amplification test for nongenital Neisseria gonorrhoeae infection in homosexual men. Clin Infect Dis 2008;47:e25-27
27. Jin F, Prestage GP, Mao L, et al. Incidence and risk factors for urethral and anal gonorrhoea and chlamydia in a cohort of HIV-negative homosexual men: the Health in Men study. Sex Transm Infect 2007;83:113-19
28. Ghanem M, Radcliffe K, Allan P. The role of urethral samples in the diagnosis of gonorrhoea in women. Int J STD AIDS 2004;15:45-7
29. Lavelle SJ, Jones KE, Mallinson H, Webb AMC. Finding, confirming, and managing gonorrhoea in a population screened for chlamydia using the Gen-Probe Aptima Combo2 assay. Sex Transm Infect 2006;82:221-24
30. FitzGerald M, Bedford C. National standards for the management of gonorrhoea. Int J STD AIDS 1996;7:298-300
31. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhoea in adults in the United States. Clin Infect Dis 2007;44:S84-101
32. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995;20(Suppl. 1):S47-65.
33. Moran JS, Zenilman JM. Therapy for gonococcal infections: options in 1989.Rev Infect Dis 1990;12(Suppl. 6):S633-44
34. Tapsall J. Current concepts in the management of gonorrhoea. Expert Opin Pharmacother 2002;3:147-57
35. Ison CA, Mouton JW, Jones K, et al. Which cephalosporin for gonorrhoea? Sex Transm Infect 2004;80:386-88
36. Korting HC, Kollman M. Effective single dose treatment of uncomplicated gonorrhoea. Int J STD AIDS 1994;5:239-43
37. Bignell CJ. Antibiotic treatment of gonorrhoea-clinical evidence for choice. Genitourin Med 1996;72:315-20
38. Echols RM, Heyd A, O' Keeffe BJ, Schacht P. Single-dose ciprofloxacin for the treatment of uncomplicated gonorrhoea: a worldwide summary. Sex Transm Dis 1994;21:345-52
39. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2006. MMWR 2006;55:42-9. See www.cdc.gov/std/treatment (last accessed 1 September 2011)
40. Health Protection Agency. Gonococcal Resistance to Antimicrobial Surveillance Programme (GRASP) Year 2007 Report. See http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1221117895841 (last accessed 10 February 2010)
41. Gonococcal Resistance to Antimicrobials Surveillance Programme in England and Wales (GRASP): report of 2009 data Health Protection Report Vol. 4, No. 34-27, August 2010. See http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1245914960426 (last accessed 10 February 2010)
42. Martin IMC, Hoffman S, Ison CA. European Surveillance of Sexually Transmitted Infections (ESSTI): the first combined antimicrobial susceptibility data for Neisseria gonorrhoeae in western Europe. J Antimicrob Chemother 2006;58:587-93
43. Chisholm SA, Neal TJ, Alawattagama AB, et al. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother 2009;64:353-58
44. Ison CA, Hussey J, Sankar KN, et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011;16:pii1/419833. See http://www.eurosurveillance.org/ViewArticle.aspx?Articleld1/419833 (last accessed 1 September 2011)
45. Forsyth S, Penney P, Rooney G. Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations. Int J STD AIDS 2011;22:296-97
46. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009;7:821-34
47. Chisholm S, Mouton J, Lewis D, et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamics rethink? J Antimicrob Chemother 2010;65:2141-18
48. Furuya R, Nakayama H, Kanayama A, et al. In vitro synergistic effects of double combinations of B lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother 2006;12:172-76
49. Sathia L, Ellis B, Philip S, et al. Pharyngeal gonorrhoea-is dual therapy the way forward? Int J STD AIDS 2007;18:647-48
50. Lo JYC, Ho KM, Leung AOC, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicro Agents Chemother 2008;52:3564-7
51. Novak E, Paxton LM, Tubbs HJ, et al. Orally-administered cefpodoxime proxetil for the treatment of uncomplicated gonococcal urethritis in males: a dose-response study. Antimicrob Agents Chemther 1992;36:1764-5
52. Tapsall JW. Antibiotic resistance in Neisseria gonorrhoeae. Clin Infect Dis 2005;41:S263-8
53. Moran JS. Ciprofloxacin for gonorrhea-250 mg or 500 mg? Sex Transm Dis 1996;23:165-7
54. Handsfield HH, Dalu ZA, Martin DH, et al. Multicenter trial of single-dose azithromycin vs ceftriaxone in the treatment of uncomplicated gonorrhoea. Sex Transm Dis 1994;21:107-11
55. Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS 1997;8:299-302
56. Tapsall JW, Schultz TR, Limnios EA, et al. Failure of azithromycin therapy in gonorrhoea and discorrelation with laboratory parameters. Sex Transm Dis 1998;25:505-08
57. Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin allergic patients: a meta-analysis. Otolaryngol-Head Neck Surg 2007;136:340-47
58. Roche Products Limited. SPC Rocephin. See http://emc.medicines.org.uk/medicine/1729/SPC/Rocephin+250mg,+1g+and+2g+vials/ (last accessed 5March 2010)
59. Brocklehurst P. Antibiotics for gonorrhea in pregnancy. Cochrane Database Syst Rev 2002;2:CD000098
60. Cavenee MR, Farris JR, Spalding TR, et al. Treatment of gonorrhea in pregnancy. Obstet Gynecol 1993;81:33-38
61. Ramus RM, Sheffield JS, Mayfield JA, Wendel GD. A randomised trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhoea in pregnancy. Am J Obstet Gynecol 2001;185:629-32.
62. Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis 1995;22:39-47
63. Tapsall J, Read P, Carmody C, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009;58:683-87
64. FitzGerald M, Thirlby D, Bell G, Bedford C. National standards for contact tracing in gonorrhoea. Int J STD AIDS 1996;7:301
65. Society for Sexual Health Advisers. The SSHA manual for sexual health advisers. See http://www.ssha.info/resources/manual-for-sexualhealth-advisers/(last accessed 27 February 2010)
66. Bachmann LH, Desmond RA, Stephens J, et al. Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhoea. J Clin Microbiol 2002;40:3596-601
67. Komolafe AJ, Sugunendran H, Corkill JE. Gonorrhoea: test of cure for sensitive bacteria? Use of genotyping to disprove treatment failure. Int J STD AIDS 2004;15:212
68. Low N, Welch J, Radcliffe K. Developing national outcome standards for the management of gonorrhoea and genital chlamydia in genitourinary medicine clinics. Sex Transm Infect 2004;80:223-9
69. Medical Foundation for AIDS & Sexual Health (MedFASH). Standards for the Management of Sexually Transmitted Infections (STIs). See http://www.medfash.org.uk/Projects/BASHH%20standards/Final%20pdfs/Standards_for_the_management_of_STIs.pdf (last accessed 5 March 2010)
70. Holland TM, Hussey J, Pattman RS, et al. Audit of gonorrhoea test of cure at the genitourinary medicine department in Newcastle-upon-Tyne, UK. Int J STD AIDS 2003;14:630-631